mpm capital  powering breakthroughs in life sciences mpm focus area personalized therapeutics forgenetically defined cancerwatch now chris bardon md oncology impact funddiscusses advances in cancer therapies bloomberg capital markets june  related investment epizyme companies mpm investment strategy mpm capital works with leading scientists to create companies that seek to address unmet needs and change the face of medicine across all therapeutic areas mpm is currently investing out of bv its most recent venture fund in  mpm partnered with ubs to create the ubs oncology impact fund oif an innovative impact investing fund focused exclusively on oncology that will invest in both private and public equities oif will support both basic cancer research as well as access to cancer care in developing countries fund all bv oncology impact fund investments current exited exit type all ipo ma focus area all oncology other andme genetic reports for consumers to better appreciate their ancestry other current  smallmolecule therapeutics that modulate mirnas for treatment oncology current affymax inc previously committed to developing novel drugs other exited aires clinical stage pharmaceutical company for pulmonary disorders other exited alinea pharmaceuticals inc previously developed new treatments for metabolic conditions other exited allozyne inc cancer and inflammatory disease therapeutic company oncology exited alnara orallydelivered protein therapeutics to treat metabolic diseases other exited amphivena developing bispecific tandabs as a novel immunotherapy for hematological disorders oncology current anthera developing drugs for autoimmune diseases other exited aratana provides innovative therapies for companion animals other current archus orthopedics inc previously developed implants to treat spine disorders other exited aryx therapeutics inc previously focused on molecular design other exited astute medical improving the diagnosis of highrisk medical conditions other current atopix therapeutics inc developing novel treatments for asthma other exited barrier therapeutics inc specialized in dermatological creams and gels other exited biomarin innovative therapeutics to patients with serious unmet medical needs other exited blade therapeutics a discovery stage company focused on developing fibrosis treatments other current celladon developing a transformative therapy for heart failure other exited cellerant therapeutics inc novel immunotherapies for oncology and bloodrelated disorders oncology exited cerecor inc developing innovative treatments for patients with cns disorders other exited ceregene inc development and manufacturing of gene therapies other exited cerimon pharmaceuticals inc developed and commercialized therapeutics for autoimmune diseases other exited chf solutions inc manufactures medical devices for cardiac care other exited chiasma developing oral drugs that were previously only available by injection other current clinical ink modernize clinical trials with esource  patient engagement tools other current conatus developing novel therapeutics for liver diseases other exited costim developing novel antibodies for cancer immunotherapy oncology exited cotherix inc licensing of therapeutic products for cardiopulmonary diseases other exited digitx partners digital health investment partnership with astellas pharma other current dragonfly sciences inc developing a new class of biosimilar products other exited ekr therapeutics provides acutecare specialty products other exited elixir pharmaceuticals inc develops novel pharmaceuticals for the treatment of metabolic diseases other exited endogastric solutions inc endoluminal treatment of gastroesophageal reflux disease other exited endologix provides optimal solutions for endovascular aortic repair other current enteromedics inc developer of vbloc® neurometabolic therapy other current epizyme personalized therapeutics for patients with genetically defined cancer oncology current fortebio develops analytical systems that enable realtime analysis of biomolecular interactions other exited harpoon therapeutics t cell redirection to deliver deep remissions oncology current helicos biosciences corporation genetic analysis for the research drug discovery and diagnostics other exited hypnion inc development of novel therapeutics for cns disorders other exited iconic developing therapeutics for serious eye disorders other current idenix discovers and develops drugs for human viral diseases other exited idun pharmaceuticals inc other exited innovative spinal technologies inc developed treatments for spinal disorders other exited intercell ag modern prophylactic and therapeutic vaccines other exited intracel holdings corporation development and commercialization of cancer vaccines other exited iomx therapeutics ag targeting t cell evasion to treat cancer oncology current ipierian developing antitau protein antibodies for neurodegenerative disease other exited kalobios pharmaceuticals inc developing monoclonal antibodies for cancer care oncology exited macrogenics inc oncology exited maverick therapeutics inc inducible t cellredirecting antibodies oncology current memory pharmaceuticals corp developed drug candidates for the treatment of cns disorders other exited meritage pharma treatment for eosinophilic esophagitis eoe other exited mitobridge discovers and develops novel drugs that enhance mitochondrial function other current motus therapeutics inc developing therapies for severe gastric mobility disorders other exited neosil manufactures dermatologyfocused specialty pharmaceutical products other exited neovista inc technologies for age related mucular degeneration other exited neuromed pharmaceuticals inc produces pain therapies in the us other exited nevro developing a highfrequency stimulation technology for chronic pain other exited oncorus developing a nextgeneration immunotherapy platform to treat cancer oncology current oxagen limited a privatelyheld biopharmaceutical company other current pacira acute care products including exparel for postsurgical analgesia other exited peptimmune inc designs peptides for therapeutics diagnostic kits  antibodies other exited pernix therapeutics inc specialty primary care and generic medicines other exited pharmasset discovering and developing novel drugs to treat viral infections other exited pharmathene inc acquire and develop products identified as urgent priorities other exited poniard pharmaceuticals inc discovery development and commercialization of oncology products other exited portola pharmaceuticals inc a biopharmaceutical company in the hematologic diseases fields other exited potenza therapeutics developing novel immunotherapies for the treatment of cancer oncology current proteon therapeutics developing a therapy to improve dialysis vascular access other current quatrx pharmaceuticals company treatment of moderate to severe dyspareunia fda approved in feb  other exited radius health novel differentiated therapeutics for patients with osteoporosis other current raze therapeutics developing novel antitumor agents through mitochondrial onecarbon me oncology current repare therapeutics targeting geneticallydefined cancer weaknesses oncology current rhythm developing peptide therapeutics for metabolic diseases other current rigel pharmaceuticals inc smallmolecule development for inflammatory and autoimmune diseases oncology exited rinat neuroscience corp develops treatment of diseases and disorders of the nervous system other exited sai drug discovery development and manufacturing services other exited selexys developing novel products to treat inflammatory diseases other exited semma therapeutics developing cellbased transformative therapies for diabetes patients other current sideris pharmaceuticals inc development of new treatments for transfusion related iron overload other exited solasia developing commercializing oncology  oncology supportive care drugs oncology exited somaxon pharmaceuticals inc developed silenor for treatment of insomnia other exited surface logix inc enhancing molecular functionality of pharmaceuticals other exited syndax developing and commercializing epigenetic therapies for cancer oncology current tcr inc focused on engineering t cells for cancer therapy oncology current tercica inc developed increlex for treatment of primary igf deficiency other exited tetherex pharmaceuticals corporation operates in the healthcare industry focusing on biotechnology business other current theraclone sciences inc screening technology for antibodies that ward off disease other exited tizona therapeutics inc regulatory t cell suppression as a novel approach to fighting cancer oncology current trieza therapeutics immunomodulatory oncolytic virus therapeutics oncology current trinetx platform to improve clinical research study design  recruitment other current true north therapeutics developing drugs which selectively inhibit the complement system other exited vaccinogen inc personalized vaccines to fight disease oncology other current valeritas marketing a disposable insulin delivery device other current vascular developing a novel antibody for diabetic nephropathy other current verastem inc treating cancer by the targeted killing of cancer stem cells oncology exited verus pharmaceuticals inc pediatricoriented specialty pharmaceutical company other exited xanodyne pharmaceuticals inc integrated specialty pharmaceutical company other exited mpm team mpms team is comprised of innovators entrepreneurs executives  investors role investment team medical  scientific advisors operations team location all cambridge san francisco patrick baeuerle patrick baeuerle phd managing director cambridge read bio chris bardon christiana bardon md managing director cambridge read bio vinay bhaskar vinay bhaskar phd principal san francisco read bio laura brass laura brass phd mba managing director cambridge read bio lauren cauley lauren cauley chief financial officer cambridge read bio thomas ebeling thomas ebeling medical and scientific advisor oif read bio stephen elledge stephen j elledge phd medical and scientific advisory board mpm  oif read bio luke evnin luke evnin phd managing director san francisco read bio mitchell finer phd mitchell finer phd managing director cambridge read bio todd foley todd foley mba managing director cambridge read bio shinichiro fuse shinichiro fuse phd principal cambridge read bio ansbert gadicke ansbert gadicke md managing director cambridge read bio bard geesaman bard geesaman md phd managing director cambridge read bio william greene william greene md venture partner san francisco read bio william hahn william c hahn md phd medical and scientific advisor oif read bio dan hicklin dan hicklin phd managing director cambridge read bio robert horvitz h robert horvitz phd medical and scientific advisory board mpm  oif read bio ed hurwitz ed hurwitz jd mba managing director san francisco read bio briggs morrison briggs morrison md managing director cambridge read bio vas narasimhan vas narasimhan md medical and scientific advisory board mpm read bio gary patou gary patou md managing director san francisco read bio sarah reed sarah reed chief operating officer and general counsel cambridge read bio tony rosenberg tony rosenberg managing director cambridge read bio david ryan david p ryan md medical  scientific advisor oif read bio kazumi shiosaki kazumi shiosaki phd managing director cambridge read bio greg sieczkiewicz greg sieczkiewicz jd phd managing director  chief ip counsel cambridge read bio elizabeth stoner elizabeth stoner md managing director cambridge read bio chris varma chris varma phd entrepreneurinresidence cambridge read bio contact us infompmcapitalcom cambridge ma  kendall street cambridge ma  phone   see full map  get directions san francisco ca  gateway boulevard suite  south san francisco ca  phone   see full map  get directions print terms of use  disclosures  july   mpm’s chris bardon talks to bioworld about recent pharma rd restructuring trends point to pharma focus on signing more early stage partnerships july   radius health appoints jesper høiland as president and chief executive officer leading the next stage of growth and value creation as a fully integrated commercial biotech company june   semma therapeutics mentioned in wsj article “biotech startups’ cellbased diabetes attack” june   mpm and versant venture colead series a financing of repare therapeutics june   proteon therapeutics announces  million private placement june   visionary scientist stephen j elledge joins mpm capital’s medical and scientific advisory board june   accomplished oncologist and scientist william c hahn joins mpm capital’s oncology impact fund advisory board june   tcr therapeutics to debut positive solid tumor data on its novel truc™ engineered t cell platform at the world preclinical congress june   radius presents positive data from a fully enrolled ongoing phase i study for investigational drug elacestrant rad at the  american society of clinical oncology annual meeting asco may   amgen vet patrick baeuerle inspires a m round from alist vcs for a nextgen io drug platform may   harpoon therapeutics announces completion of m series b financing may   mpm portfolio company true north therapeutics acquired by bioverativ inc upfront payment of m plus assumed cash with additional payments of up to m contingent on the achievement of future milestones may   syndax shares soar as lead drug clears a midstage cancer drug study hurdle may   conatus announces exercise of license option for global development and commercialization of emricasan following notice of initiation of phase b encorelf clinical trial in nash cirrhosis may   inside perspectives on cancer immunotherapy an interview with mpm’s christiana bardon april   fda approves mpm portfolio company radius health’s tymlos™ abaloparatide bone building agent for the treatment of postmenopausal women with osteoporosis at high risk for fracture april   meet one the most successful german biotech leaders ever read more about mpm’s patrick baeuerle april   mpm managing director chris bardon named a top transformer top innovation gurus leading the biopharma industrys transformation are recognized by mmm april   mpm portfolio company oncorus nominated for  nevy award as hottest earlystage startup therapeutics april   syndax pharmaceuticals adds biopharmaceutical industry leader keith a katkin to board of directors february   rhythm announces completion of  million mezzanine financing — proceeds to finance significant expansion of genetic obesity clinical trials — february   chris varma cofounder and former president and ceo of blueprint medicines joins mpm as entrepreneurinresidence january   mpm portfolio company maverick therapeutics and takeda announce fiveyear collaboration to advance tcell engagement therapies january   accomplished biotech investor ed hurwitz joins mpm as managing director  december   mpm portfolio company astute medical forms strategic partnership with biotechne december   novartis signs exclusive option collaboration and license agreement with mpm portfolio company conatus pharmaceuticals inc december   oncorus® inc announces additional series a financing support from astellas venture management llc december   harpoon therapeutics appoints gerald mcmahon phd as president and ceo december   tcr therapeutics launches from stealth mode to accelerate development of novel cancer immunotherapies  m series a financing led by mpm capital and f ventures  december   chris bardon mpm managing director comments to bloomberg on new approaches to medical philanthropy read full article – “a few billionaires are turning medical philanthropy on its head” november   epizyme announces fast track designation for tazemetostat in dlbcl and provides tumor program update november   novartis acquires mpm portfolio company selexys pharmaceuticals corporation and selg antibody for reduction of pain crises in sickle cell disease november   harpoon therapeutics appoints hanspeter gerber phd as chief scientific officer november   semma therapeutics announces mark fishman md has joined its board of directors as chairman october   mpm portfolio company epizyme expands clinical programs through cooperative research and development agreements with the national cancer institute october   motus therapeutics inc a subsidiary of mpm portfolio company rhythm holding co llc is to be acquired by allergan acquisition announced following positive results for phase b clinical trial of treatment for gi disorders october   true north therapeutics receives fda orphan drug designation for tnt for the treatment of autoimmune hemolytic anemia including cold agglutinin disease cad october   pacira pharmaceuticals’ kristen williams is honored as  of  “fierce women in biopharma ” learn why kristen stands out among women in the industry september   iomx therapeutics raises eur  million in series a round company establishes toptier investor base consisting of mpm capital sofinnova partners wellington partners and merck ventures september   three mpm portfolio companies blade oncorus  rhythm named to fiercebiotech’s “ fierce ” list september   radius announces publication of additional positive results from the phase  active trial of osteoporosis treatment september   tizona therapeutics inc appoints george golumbeski phd to its board of directors august   osteoporosis a disease with few treatment options may soon have one more read coverage in ny times and in press release august   aratana secures third fda approval animal pain drug expected to be available to veterinarians in the fall of  august   harvard medical school appoints mpm medical and scientific advisory cochair george daley as new dean read more in the boston globe august   iconic therapeutics announces final close of series c financing with additional  million investment august   astellas and mpm capital launch digitx partners july   mpm portfolio company blade therapeutics featured in the san francisco business times the july  article “taking it personally cutting–edge biotech snags  million” discusses the latest round of funding for blade a company focused on finding therapies for fibrotic disease and mpm cofounder luke evnin’s personal commitment to the cause july   rhythm announces new england journal of medicine publication of setmelanotide phase  data for treatment of pomc deficiency obesity significant weight loss with targeted treatment for patients with rare genetic defect in critical weight regulation pathway july   former bluebird bio blue cso takes the reins at oncorus startup launches with  million series a june   mpm portfolio company semma therapeutics featured in boston globe bostonarea hospitals have teamed up with the harvard stem cell institute and semma therapeutics to make personalized cellbased therapies and organize clinical trials june   chris bardon managing director for the oncology impact fund on bloomberg capital markets discussing advances in cancer therapies as the  asco annual meeting gets underway may   trinetx enters into collaboration with celgene advance clinical trial design and research for nextgeneration medicines planned may   aratana therapeutics granted fda approval of entyce® firstofitskind ghrelin mimetic may   mpm launches  million social impact oncology fund april   ubs cancer fund shows power of impact investing a new oncology fund will finance academic research and access to cancer care in developing countries april   ubs mpm seek big ‘impact’ in cancer drugs with m fund by marie powers bioworld today april   april   ubs raises record  million for oncology impact fund biospacecom  march   aratana therapeutics granted first fda approval galliprant for the control of pain and inflammation associated with osteoarthritis in dogs march   chiasma initiates phase  trial to support european registration of octreotide capsules for patients with acromegaly march   tizona therapeutics inc completes  million series b financing march   radius health submits new drug application to the us food and drug administration for abaloparatidesc for the treatment of postmenopausal women with osteoporosis march   nasdaq welcomes syndax parmaceuticals inc to the nasdaq stock market january   iconic therapeutics closes series c financing  october   semma therapeutics named fiercemedicaldevices’  fierce  august   syndax enters clinical trial collaboration in cancer immunotherapy combining entinostat and atezolizumab august   syndax raises  million in series c financing august   rhythm subsidiary raises  million in oversubscribed financing financing to advance rhythm metabolic incs setmelanotide program for rare genetic disorders of obesity august   epizyme appoints robert bazemore president and chief executive officer july   chiasma inc prices initial public offering of common stock july   taking clinical trials out of the dark ages clinical ink june   briggs w morrison md ceo of syndax appointed key strategic advisor to mpm capital june   chiasma submits new drug application to us fda for octreotide capsules in acromegaly submission based on positive results from phase  clinical trial june   k peter hirth phd joins iconic therapeutics as board member and senior scientific advisor may   mpm capital appoints pablo j cagnoni md former onyx pharmaceuticals president as managing director and ceo of mpm immunotherapy portfolio company vesuvius may   mpm closes  million fund may   andme launches the lupus research study in collaboration with pfizer inc with lupus awareness month underway study aims to build a patient lupus cohort to advance understanding of the disease april   astellas pharma and potenza therapeutics partner to build a portfolio of immunooncology therapeutics exclusive collaboration includes option for astellas to acquire potenza april   novartis international global head ma and licensing anthony rosenberg to join as managing director effective april    to serve as strategic advisor and on mpm portfolio boards to build leading companies  march   biotech startup to fight diabetes on the cellular front semma therapeutics seeks to turn success in stem research lab into a way to encourage insulin production march   semma therapeutics announces  million in funding led by mpm capital to develop cell therapy for treating type  diabetes signs agreement with global pharmaceutical company march   ebb  flow chiasma’s private decision march   chiasma announces mark leuchtenberger as chief executive officer proven business leader to oversee commercialization of octreotide capsules march   andme to create therapeutics group appoints scientific luminary rd executive richard scheller phd to lead dr scheller joins andme’s executive leadership team as chief science officer and head of therapeutics march   mpm capital announces immunooncology pioneer patrick baeuerle to serve as managing director top scientist and drug developer joins mpm senior team advancing breakthroughs and discoveries march   radius rdus announced today that it has acquired the license to develop and market rad in japan dinesh purandare hired former sanofi sanpa oncology executive to the position of senior vice president svp and head of global oncology at radius  february   chiasma announces completion of  million series e financing february   verastem receives orphan drug designation from fda for vs in mesothelioma february   chiasma appoints david stack as chairman of the board john a scarlett md joins board of directors february   syndax says immunooncology discovery happened instead of an ipo february   chiasma inc releases newly published phase  study results show positive outcomes for octreotide capsules in people with acromegaly a serious hormonal disorder february   radius celladon and nevro among top ipos in  mpm has   and  out of the top  january   radius the top performing ipo of  radius which is developing treatments for osteoporosis is up  since pricing its june  initial public offering at   december   radius announces positive phase  topline results december   for venture capital biotech is where it’s really at august   aratana featured startups work on biotech drugs for pets june   true north snags m and sets course for the clinic with a rare disease drug april   ipierian acquired by bristolmyers squibb advances discovery strategy to pursue therapeutics for genetically defined diseases april   iconic therapeutics raises  million to advance clinical development of wet amd program william greene md appointed chief executive officer april   celladon receives breakthrough therapy designation from fda mydicar is first gene therapy reported to receive breakthrough designation from fda’s center for biologics evaluation and research cber february   costim pharmaceuticals inc acquired by novartis january   mpm capital and kleiner perkins caufield  byers top the list of investors with the most  ipos january   epizyme and celgene advance epz dotl inhibitor clinical program to benefit cancer patients with acute leukemias achieving  million clinical proof of concept milestone     x x x summit investors ge ixvc iv llc  pooled investment fund allgaier formdscom  sec filings of fundraisings and investments in hedge funds private equity firms startups and growing companies formdscom newest filter local summit investors ge ixvc iv llc industry pooled investment fund see others in industry address  berkeley street  th floor boston ma phone  filings date filingtype reported sold incremental cash type exemptions link to raw filing  new yet to sell  equity only b c c sec link  new yet to sell  equity only b c c sec link  new yet to sell  equity only b c c sec link  new yet to sell  equity only b c c sec link directors and executives current and past name role matthias g allgaier executive darren m black executive john r carroll executive peter y chung executive scott c collins executive christopher j dean executive mark a delaar executive robin w devereux executive bruce r evans executive leonard c ferrington executive charles j fitzgerald executive craig d frances executive james m freeland executive greg s goldfarb executive todd d hearle executive thomas h jennings executive walter g kortschak executive martin j mannion executive gregg j nardone executive thomas s roberts executive peter l rottier executive han sikkens executive christian r strain executive alexander d whittemore executive alexander d whittmore executive peter rottiers involvement in venture capital via summit investors ge ixvc iv llc perforce holdings inc want to see morewant to find out who got funded and who’s funding the next big thing in real time all across the world tailored to your specific areas of focus deals per dayget access to the most exhaustive worldwide funding watch on the webcomprehensive funding informationknow about who invested in a company which sites covered the event the funding history etcexclusive insightsview original analytics such as most dynamic industries most active investors and morestay awareget emailed when deals critical to your business happen filter by region industry and topics of interestas seen onhave a loginsign inregister nowits freeuse your social accountor fill in the quick formregister nowpromise we wont spamsign invia your social accountvia your existing wgf accountremember meregister its freeforgot your passwordsign inforgot your passwordenter your email and we will send you your new passwordreset passwordthe worlds largest funding basepeoplepeterrottiersectionpeoplesubsectiondetailid search deals by company name industry location investors search peterrottierget alertedif peter rottier gets fundedpeter rottiersummit investors ge ixvc iv llc  executive officerperforce holdings inc  directordeals involving peter rottierundisclosed raised with summit investors ge ixvc iv llc on september  raised with perforce holdings inc on february please note that all data is automatically extracted and errors can occurthe whogotfunded team has not necessarily reviewed the information in this page and has not determined if it is accurate and completesome of the profile information was collected using the crunchbase api for more details on the profile please check peter rottier on crunchbaseinaccurate data help us improve whogotfunded post a comment   summit partners  contact information summit partners connect boston menlo park london connect with us please contact us at one of our offices below or contact a member of our investment team summitpartners linkedin profile join our newsletter media inquiries meg devine boston summit partners  berkeley street th floor boston ma  united states t   f   office information menlo park summit partners  middlefield road suite  menlo park ca  united states t   f   office information london summit partners llp queensberry house rd floor old burlington street london ws ae united kingdom t     f     office information home  golub capital speed and creativity fueled by data and insights opportunity awaitsmiddle market lendingprovides senior onestop and second lien loans to us middle market companieslate stage lendingprovides flexible debt that allows fastgrowing technology companies to expand without further equity dilutionbroadly syndicated loansinvests in liquid senior secured loans to larger companiesget to know golub capitalgolub capital is a nationally recognized credit asset manager with over  billion of capital under management for over  years the firm has provided credit to help mediumsized us businesses grow the firm’s awardwinning middle market lending business helps provide financing for middle market companies and their private equity sponsors golub capital’s credit expertise also forms the foundation of its late state lending and broadly syndicated loan businesses golub capital has worked hard to build a reputation as a fast reliable provider of compelling financing solutions and we believe this has inspired repeat clients and investors today the firm has over  employees with lending offices in chicago new york and san franciscolatest newsrevenue in the us middle market grew by  in q  according to the golub capital middle market reportmiddle market private companies in the golub capital altman index experienced yearoveryear revenue growth of  and earnings defined as earnings before interest taxes depreciation and amortization or ebitda growthread moregolub capital bdc inc announces  million in new middlemarket originations for its fiscal year  third quartergolub capital bdc inc nasdaq gbdc wwwgolubcapitalbdccom a business development company today announced that it originated  million in new middlemarket investment commitments during the three months ended june read morethe case for middle market lending by david golubread more golub capital bdc incgolub capital bdc inc schedules release of fiscal year  third quarter resultsgolub capital bdc inc a business development company nasdaq gbdc wwwgolubcapitalbdccom announced today that it will report its financial results for the fiscal quarter ended june   on mondayread moregolub capital bdc inc prices public offering of  shares of common stockgolub capital bdc inc the company a business development company nasdaq gbdc announced that it has priced an underwritten public offering of  shares of its common stock ubs investmentread moregolub capital bdc inc nasdaq gbdc is a business development company that makes debt and minority equity investments in middlemarket companies that are in most cases sponsored by private equity investorsread more brightscope  advisor pages  find a financial advisor or advisory firm getsearchtypedisplaynamesearchtype advisor funds firms k plans general search advisors advisory firms financial qa k plans funds search home    brightscope advisor pages    find a financial advisory firm advisor search firm search advisors by city find a financial advisory firm search firm name active firms only city state alabama alaska american samoa arizona arkansas california colorado connecticut delaware district of columbia florida georgia guam hawaii idaho illinois indiana iowa kansas kentucky louisiana maine maryland massachusetts michigan minnesota mississippi missouri montana nebraska nevada new hampshire new jersey new mexico new york north carolina north dakota northern marinara islands ohio oklahoma oregon pennsylvania puerto rico rhode island south carolina south dakota tennessee texas utah vermont virgin islands virginia washington west virginia wisconsin wyoming firm service areas financial planning estate planning comprehensive financial planning retirement planning college planning charitable planning other financial planning tax planning insurance life insurance health insurance longterm care insurance annuities property  casualty insurance business insurance other insurance pension consulting k b  defined benefit other pension consulting portfolio management individuals andor small businesses investment companies businesses or institutional clients other portfolio management accounting  tax tax advice other tax legal legal planning legal advice other legal other publication of periodicals or newsletters security ratings or pricing services market timing services selection of other advisors educational seminarsworkshops see all service areas find filters financialplanningfindfirm compensation arrangements no preference fixed fees  hourly charges  performancebased fees  none  fee only  assets under mgmt no preference   k  m  m  m  m  m  m  b  b  avg account balance no preference   k  k  k  k  m  m  m  m  m  financial advisory firm search results  results merrill lynch pierce fenner  smith incorporated ny ny  advisors  aum  b wells fargo advisors llc st louis mo  advisors  aum  b jp morgan securities llc manhattan ny  advisors  aum  b morgan stanley smith barney llc harrison ny  advisors  aum  b lpl financial llc boston ma  advisors  aum  b edward d jones  co lp des peres mo  advisors  aum  b ameriprise financial services inc minneapolis mn  advisors  aum  b ubs financial services inc weehawken nj  advisors  aum  b northwestern mutual investment servicesllc milwaukee wi  advisors charles schwab  co inc south beach ca  advisors mml investors services llc pine point ma  advisors  aum  b goldman sachs  co ny ny  advisors  aum  b strategic advisers inc boston ma  advisors  aum  b citigroup global markets inc new york ny  advisors  aum  b raymond james  associates inc st petersburg fl  advisors  aum  b      company info about us newsroom careers contact blog explore k plan ratings advisor pages fund pages financial insights faq for advisors advisor pages spyglass for enterprise beacon social facebook twitter linkedin legal privacy policy terms of use copyright   brightscope inc all rights reserved your use of this service is subject to ourterms of useandprivacy policy information is provided as is and solely for informational purposes not for investment purposes or advicebrightscope is not a fiduciary under erisa brightscope is not endorsed by or affiliated with finra brightscope  cio  fww  global custodian  investor economics  liquidmetrix  market metrics  matrix solutions  planadviser  plan for life  plansponsor  simfund  strategic insight  the trade  strategic insight inc all rights reserved no reproduction without prior authorizations summit partners lp  financial services firm boston massachusetts  brightscope advisor pages getsearchtypedisplaynamesearchtype advisor funds firms k plans back to top homefirmpagessummit partners lp summit partners lp overviewarticlesholdingsassetsservicesadvisorsleadershipfees share summit partners lp overviewarticlesholdingsassetsservicesadvisorsleadershipfees overview description summit partners lp is a ria based in boston ma with b in aum information type ria head quarters boston ma  of employees  total assets  website location  berkeley st boston ma   articles insights there are no insights from this firm to display at this time procter  gamble plans competitive but exposure to company stock a risk to participants brightscope editorial firm links there are no links for this firm to display at this time holdings etf holdings there is no etf holding data from this firm to display at this time assets assets last updated on may   b total assets under management na total assets under advisement  accounts m estimated average account balance services firm services there is no services data available to display at this time firm client types advisors current advisors  of advisors  there are no advisors from this firm to display at this time affiliated investment advisors and broker dealers name type total assets summit accelerator partners llc iar  summit investors management llc   summit partners credit advisors lp iar  summit partners ege ii sarl   summit partners entrepreneur advisors gp ii llc   summit partners entrepreneur advisors gp llc   summit partners europe lp iar  summit partners ge ix lp   summit partners ge viii aiv lp   summit partners ge viii lp iar  summit partners llp   summit partners pe vii lp iar  summit partners public asset management llc iar  summit partners sd iii lp iar  summit partners sd iv lp iar  summit partners v lp iar  summit partners vc ii lp iar  summit partners vc iii lp iar  summit partners vc iv lp   summit partners vi gp lp iar  summit partners llc iar  leadership ownership there is no ownership data available to display at this time executives and control persons name title tenure date  ownership walter german kortschak limited partner august   to  robert g bannish personal representative of the the estate of joseph f trustey august   to  james richard westra personal representative of the the estate of joseph f trustey august   to  scott charles collins limited partner august   to  peter y chung limited partner august   to  bruce roger evans limited partner august   to  thomas scott roberts limited partner august   to  martin joseph mannion limited partner august   to  robin winters devereux chief compliance officer april  less than  source sec fees types of compensation arrangements percentage of assets performancebased fees company info about us newsroom careers contact blog explore k plan ratings advisor pages fund pages financial insights faq for advisors advisor pages spyglass for enterprise beacon social facebook twitter linkedin legal privacy policy terms of use copyright   brightscope inc all rights reserved your use of this service is subject to ourterms of useandprivacy policy information is provided as is and solely for informational purposes not for investment purposes or advicebrightscope is not a fiduciary under erisa brightscope is not endorsed by or affiliated with finra brightscope  cio  fww  global custodian  investor economics  liquidmetrix  market metrics  matrix solutions  planadviser  plan for life  plansponsor  simfund  strategic insight  the trade  strategic insight inc all rights reserved no reproduction without prior authorizations summit partners lp  financial services firm boston massachusetts  brightscope advisor pages getsearchtypedisplaynamesearchtype advisor funds firms k plans back to top homefirmpagessummit partners lp summit partners lp overviewarticlesholdingsassetsservicesadvisorsleadershipfees share summit partners lp overviewarticlesholdingsassetsservicesadvisorsleadershipfees overview description summit partners lp is a ria based in boston ma with b in aum information type ria head quarters boston ma  of employees  total assets  website location  berkeley st boston ma   articles insights there are no insights from this firm to display at this time procter  gamble plans competitive but exposure to company stock a risk to participants brightscope editorial firm links there are no links for this firm to display at this time holdings etf holdings there is no etf holding data from this firm to display at this time assets assets last updated on may   b total assets under management na total assets under advisement  accounts m estimated average account balance services firm services there is no services data available to display at this time firm client types advisors current advisors  of advisors  there are no advisors from this firm to display at this time affiliated investment advisors and broker dealers name type total assets summit accelerator partners llc iar  summit investors management llc   summit partners credit advisors lp iar  summit partners ege ii sarl   summit partners entrepreneur advisors gp ii llc   summit partners entrepreneur advisors gp llc   summit partners europe lp iar  summit partners ge ix lp   summit partners ge viii aiv lp   summit partners ge viii lp iar  summit partners llp   summit partners pe vii lp iar  summit partners public asset management llc iar  summit partners sd iii lp iar  summit partners sd iv lp iar  summit partners v lp iar  summit partners vc ii lp iar  summit partners vc iii lp iar  summit partners vc iv lp   summit partners vi gp lp iar  summit partners llc iar  leadership ownership there is no ownership data available to display at this time executives and control persons name title tenure date  ownership walter german kortschak limited partner august   to  robert g bannish personal representative of the the estate of joseph f trustey august   to  james richard westra personal representative of the the estate of joseph f trustey august   to  scott charles collins limited partner august   to  peter y chung limited partner august   to  bruce roger evans limited partner august   to  thomas scott roberts limited partner august   to  martin joseph mannion limited partner august   to  robin winters devereux chief compliance officer april  less than  source sec fees types of compensation arrangements percentage of assets performancebased fees company info about us newsroom careers contact blog explore k plan ratings advisor pages fund pages financial insights faq for advisors advisor pages spyglass for enterprise beacon social facebook twitter linkedin legal privacy policy terms of use copyright   brightscope inc all rights reserved your use of this service is subject to ourterms of useandprivacy policy information is provided as is and solely for informational purposes not for investment purposes or advicebrightscope is not a fiduciary under erisa brightscope is not endorsed by or affiliated with finra brightscope  cio  fww  global custodian  investor economics  liquidmetrix  market metrics  matrix solutions  planadviser  plan for life  plansponsor  simfund  strategic insight  the trade  strategic insight inc all rights reserved no reproduction without prior authorizations summit investors ge ixvc iv llc  funding history company info news  want to see morewant to find out who got funded and who’s funding the next big thing in real time all across the world tailored to your specific areas of focus deals per dayget access to the most exhaustive worldwide funding watch on the webcomprehensive funding informationknow about who invested in a company which sites covered the event the funding history etcexclusive insightsview original analytics such as most dynamic industries most active investors and morestay awareget emailed when deals critical to your business happen filter by region industry and topics of interestas seen onhave a loginsign inregister nowits freeuse your social accountor fill in the quick formregister nowpromise we wont spamsign invia your social accountvia your existing wgf accountremember meregister its freeforgot your passwordsign inforgot your passwordenter your email and we will send you your new passwordreset passwordthe worlds largest funding basecompaniessummitinvestorsgeixvcivllcsectioncompaniessubsectiondetailid   search deals by company name industry location investors search summit investors ge ixvc iv llccompany detailsget alertedif summit investors ge ixvc iv llc gets fundedsummit investors ge ixvc iv llcfunding history key peoplecountrystatecityunited statesmassachusettsbostonindustryfinance funding history datedeal sizeinvestors september th undisclosedview dealcreate alertmanage your alerts in accountwant to know when summit investors ge ixvc iv llc gets fundedkey peoplerobin devereuxexecutive officerbruce evansexecutive officerleonard ferringtonexecutive officercharles fitzgeraldexecutive officerjames freelandexecutive officertodd hearleexecutive officerwalter kortschakexecutive officermartin mannionexecutive officerpeter rottierexecutive officeralexander whittemoreexecutive officerplease note that all data is automatically extracted and errors can occurthe whogotfunded team has not necessarily reviewed the information in this page and has not determined if it is accurate and completeinaccurate data help us improve whogotfunded post a comment investors business daily  stock news  stock market analysis  ibd market trend market trend the big picture stock market today ibds etf market strategy psychological market indicators stock lists stock lists my stock lists ibd big cap  ipo leaders stocks near a buy zone ibd  new highs global leaders your weekly review sector leaders relative strength at new high rising profit estimates tech leaders stock spotlight can slim select stocks that funds are buying ibd data tables stocks on the move research stock research ibd stock checkup ibd charts etfs  funds investing action plan the income investor etf center earnings preview industry snapshot ibd industry themes earnings calendar short selling futures  options ibd stock analysis swing trading bonds the new america ibd data stories premium investing tools leaderboard swing trader etables top rated stocks under  marketsmith news news eibd best etfs technology etf leaders click tech blog best mutual funds fang stocks news economy retirement economic calendar personal finance real estate financial advisor briefing special reports management industry news pages politics politics editorials trump news  tweets commentary the trump economy columnists economic optimism index policy  analysis ibdtipp poll ibd videos ibd videos investing videos home study programs how to invest lesson topics getting started with ibd the can slim investing system how to time the stock market how to find and evaluate stocks how to read stock charts how to buy stocks how to sell stocks swing trading educational resources new to ibd ibd meetups ask ibd investors corner ibd key terms ibd live workshops ibd home study courses webinars leaderboard swing trader marketsmith store breaking techs lead stocks modestly lower   tobacco stocks dive as fda to lower nicotine levels shopping cart your cart is currently empty visit the ibd store to get started market trend market trend the big picture stock market today ibds etf market strategy psychological market indicators stock lists stock lists my stock lists ibd big cap  ipo leaders stocks near a buy zone ibd  new highs global leaders your weekly review sector leaders relative strength at new high rising profit estimates tech leaders stock spotlight can slim select stocks that funds are buying ibd data tables stocks on the move research stock research ibd stock checkup ibd charts etfs  funds investing action plan the income investor etf center earnings preview industry snapshot ibd industry themes earnings calendar short selling futures  options ibd stock analysis swing trading bonds the new america ibd data stories premium investing tools leaderboard swing trader etables top rated stocks under  marketsmith news news eibd best etfs technology etf leaders click tech blog best mutual funds fang stocks news economy retirement economic calendar personal finance real estate financial advisor briefing special reports management industry news pages politics politics editorials trump news  tweets commentary the trump economy columnists economic optimism index policy  analysis ibdtipp poll ibd videos ibd videos investing videos home study programs how to invest lesson topics getting started with ibd the can slim investing system how to time the stock market how to find and evaluate stocks how to read stock charts how to buy stocks how to sell stocks swing trading educational resources new to ibd ibd meetups ask ibd investors corner ibd key terms ibd live workshops ibd home study courses webinars leaderboard swing trader marketsmith store hi my ibd sign out my products my favorites my stock lists edit sign in shopping cart hi sign out my products my favorites edit my stock lists indexes mostly down gop health failure hurts this stock as alibaba bounces back this chinese stock may soon break out is the holy grail of digital payments one click away apple headlines busy week of earnings and potential option trades as paypal square rise this prepaid card stock may cash in fda acts vs cigarettes but one tobacco giant is holding up mastercard visa make big cap  both still early stage chevron exxon stay aggressive in permian not holding back amazon miss sparks debate will video pay off like cloud computing get ibds newsletters delivered to your inbox daily thanks youll start receiving the best of ibd in your inbox please select a newsletter to subscribe to market prep tech report sign up please enter a valid email address get these newsletters delivered to your inbox and more info about our products and services privacy policy todays spotlight best online broker survey ibd wants to know how satisfied you are with your online broker begin survey get marketsmith premium sink your teeth into profits when you catch the next big stock winner take a week trial for just  try marketsmith today signs your stock may be topping in this free webinar we cover three signs of weakness reversal days stalling and churning watch archive market trend stock market today indexes mostly down gop health failure hurts this stock  pm etedwards lifesciences may have been hurt because of the defeat of the republican skinny repeal stock lists best stocks to buy and watch  am et build and maintain your watch list with the latest news and analysis of the markets research earnings calendar analyst estimates and stocks to watch  am et build your watch list and action plan with a look at stocks set to report see what adding futures can do for your trading strategy understand the markets try our practice simulator then start trading everything you need to add futures and capitalize on new opportunities is right here promoted content by cme group ibd stock lists sector leaders ibd’s most stringent and powerful screen sector leaders highlight the best stocks in ibd’s  sectors all sector leaders show outstanding earnings and sales growth in recent quarters and are strong across many other fundamental and priceperformance metrics abbvies humira hit the brake in q stock dives abbvie topped secondquarter sales and adjusted profits expectations early friday abbvie topped secondquarter sales and adjusted profits expectations early friday these  europetracking etfs climb near buy points the major european stock indexes have been trending lower for weeks or months but three etfs that track the continent the major european stock indexes have been trending lower for selling leaves these  spotlight stocks back near buy points a turnabout day on the market left ibd’s stock spotlight list showing some resilience and some stocks back near or a turnabout day on the market left ibd’s stock spotlight astrazeneca beats but stock dives on drug failure  more report astrazeneca topped profit views but shares crashed on an immunooncology setback roche also beat astrazeneca topped profit views but shares crashed on an immunooncology investing resources subscribe to theibd digital edition get  free weeks of the ibd digital edition plus access to ibds exclusive market analysis proprietary stock ratings and interactive tools watch learn and listen with ibd videos stay on top of the market with ibds exclusive videos you will find the latest news market analysis and education to help you become a more successful investor getting started with ibd get the most out of ibds products and features by learning the can slim investing system and staying in sync with the market trend